3.070USD+1.32%Mkt Cap: 220.72M USDP/E: —Last update: 2026-05-26
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen re…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap220.72M USD
Enterprise Value61.35M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-104.08M USD
Revenue/Share—
Last Price3.070 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees108
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.76
PEG—
EV/EBITDA-0.58
EV/Revenue—
P/S—
P/B0.69
EPS (TTM)-1.46
EPS (Forward)-1.73
52W Range
1.63071% of range3.650
52W High3.650 USD
52W Low1.630 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-33.33%
ROA-25.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.70M USD
CapEx (TTM)1.21M USD
FCF Margin—
FCF Yield-26.00%
Net Debt-155.43M USD
Net Debt/EBITDA1.47
Balance Sheet
Debt/Equity0.24
Current Ratio12.96
Quick Ratio12.75
Book Value/Sh4.394 USD
Cash/Share3.221 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)11.20 USD
Target Range9.000 USD – 16.00 USD
# Analysts5
Ownership
Shares Out.71.55M
Float60.45M
Insiders4.88%
Institutions80.45%
Short Interest
Short Ratio5.6d
Short % Float9.26%
Short % Out.7.40%
Shares Short5.27M
Short (prev mo.)5.53M
Technical
SMA 502.626 (+16.9%)
SMA 2002.239 (+37.1%)
Beta0.89
S&P 52W Chg28.31%
Avg Vol (30d)976.81K
Avg Vol (10d)670.75K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—